Democratizing Patient Care Through Digital and Virtual-First Care Solutions

Living through a global pandemic has shown that we can use technology to modernize and enhance patient care. Digital and virtual-first health solutions are here to stay–and there is a desperate pharma, provider, and patient need for continuity of care through real-time, easily accessible data sharing and increased access to evidence-based interventions. Yet digital health solutions, while sorely needed and on the rise, are not always in the wheelhouse of traditional biopharma companies. Partnering is clearly needed–and alliance managers will be called upon to step into the breach.

Biopharma veteran Alex Waldron, CEO of Wellinks, will show how alliance management can help break down traditional silos and drive collaborative innovation, and how his company is evolving the virtual care landscape for people with Chronic Obstructive Pulmonary Disease (COPD)–the third leading cause of death by disease in the US–bringing a better standard of care to the largely older, more rural COPD patient population by means of digital and virtual-first solutions.

Conference Keynote:

Alex Waldron
Chief Executive Officer

Alex Waldron is chief executive officer at Wellinks, a healthcare company on a mission to help patients with COPD live fully and breathe freely. Offering the first-ever integrated, virtual COPD management system, Wellinks supports patients through virtual pulmonary rehabilitation, health coaching, and monitoring through connected devices and an easy-to-use smartphone app.

Alex is a global healthcare business executive with 25+ years of experience leading large pharmaceutical, fully integrated biopharmaceutical, digital healthcare, and startup organizations. In previous roles, Alex was one of the original members of the Pear Therapeutics management team, architected the structure and growth of several divisions at Biogen, and helped to shape the emerging biosimilar market at Epirus Biopharmaceuticals. Alex has also worked in numerous commercial and operations roles at Genzyme, Astra Zeneca, Pfizer and Bristol-Myers Squibb.